- Home
- SNV vs MDGL Comparison
SNV vs MDGL Comparison
Compare SNV & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNV
- MDGL
- Stock Information
- Founded
- SNV 1888
- MDGL 2011
- Country
- SNV United States
- MDGL United States
- Employees
- SNV N/A
- MDGL N/A
- Industry
- SNV Major Banks
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- SNV Finance
- MDGL Health Care
- Exchange
- SNV Nasdaq
- MDGL Nasdaq
- Market Cap
- SNV 6.8B
- MDGL 6.1B
- IPO Year
- SNV N/A
- MDGL N/A
- Fundamental
- Price
- SNV $50.55
- MDGL $414.68
- Analyst Decision
- SNV Buy
- MDGL Strong Buy
- Analyst Count
- SNV 22
- MDGL 8
- Target Price
- SNV $59.95
- MDGL $445.71
- AVG Volume (30 Days)
- SNV 2.2M
- MDGL 469.6K
- Earning Date
- SNV 10-15-2025
- MDGL 08-05-2025
- Dividend Yield
- SNV 3.18%
- MDGL N/A
- EPS Growth
- SNV 218.56
- MDGL N/A
- EPS
- SNV 5.20
- MDGL N/A
- Revenue
- SNV $2,239,379,000.00
- MDGL $515,547,000.00
- Revenue This Year
- SNV $29.99
- MDGL $286.67
- Revenue Next Year
- SNV $5.27
- MDGL $67.98
- P/E Ratio
- SNV $9.74
- MDGL N/A
- Revenue Growth
- SNV 32.95
- MDGL 3421.98
- 52 Week Low
- SNV $35.94
- MDGL $200.63
- 52 Week High
- SNV $61.06
- MDGL $419.99
- Technical
- Relative Strength Index (RSI)
- SNV 53.30
- MDGL 77.54
- Support Level
- SNV $48.82
- MDGL $351.32
- Resistance Level
- SNV $50.34
- MDGL $393.76
- Average True Range (ATR)
- SNV 1.19
- MDGL 17.32
- MACD
- SNV 0.29
- MDGL 6.15
- Stochastic Oscillator
- SNV 84.39
- MDGL 94.95
About SNV Synovus Financial Corp.
Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products & services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, & international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.